Ag-Bio Alliance With Monsanto Brings Alnylam Cash For “5x15” Programs
This article was originally published in The Pink Sheet Daily
Alnylam will license its IP estate to agriculture giant Monsanto over 10 years, in turn getting a $29.2 million upfront payment that it will put toward further development of RNAi therapeutics.
You may also be interested in...
The RNA interference pioneer will focus on two candidates, ALN-TTR02 for transthyretin-mediated amyloidosis and ALN-APC for hemophilia, while seeking partners for its other “5x15” programs.
With $20.7 Million Series A Cash, RaNA Seeks To Be A Groundbreaker In Long Non-Coding RNA Therapeutics
Biotech hopes to begin IND-enabling studies in 2013 and bring first candidate into the clinic in 2014 in a new field it believes will have applicability in numerous therapeutic areas.
Programs only allowed for brands with generic competition under court ruling, but related programs such as copay maximizers and so-called ‘alternative funding’ programs are not directly impacted by the decision.